Page URL:

Study shows how gene therapy caused leukaemia

17 October 2003
By BioNews
Appeared in BioNews 230

US and European scientists have published results confirming that a gene therapy technique triggered leukaemia in two boys taking part in a trial at the Necker hospital, Paris. Their findings, which appear in Science, show that the virus used to deliver the therapeutic gene activated a cancer-causing gene. Eleven boys with X-linked severe combined immune deficiency (X-SCID) underwent experimental gene therapy treatment at the French hospital, but the trial was halted in October 2002, after one of the boys developed leukaemia symptoms. When a second patient developed leukaemia, in January 2003, similar trials in several countries were suspended. Most, including one at London's Great Ormond Street Hospital, have now resumed, but only for patients with no other treatment options.

Children affected by SCID have a faulty gene that means they have no working immune system, so their bodies cannot fight infections. This life-threatening condition is sometimes called 'bubble boy' disease, as unless they can be successfully treated with a matched bone marrow transplant, patients must spend their lives in a sterile environment. To carry out the gene therapy treatment, the French researchers harvested bone marrow from the patients, from which they isolated blood stem cells. They then infected these cells with a retrovirus (a virus that inserts its genetic material into the host cell's DNA) carrying a working gene, before returning the modified cells back to the patients.

Ten patients initially responded well to the treatment, but two later developed leukaemia: cancer of the bone marrow. In both cases, researchers found that the retrovirus had inserted its genetic material close to the 'on-switch' of a cancer-causing gene called LMO2. It is thought that this event caused the unregulated growth of the bone marrow cells, which in turn triggered the leukaemia, although other factors could have been involved. The two boys are reported to have responded well to chemotherapy and bone marrow transplant treatment, and are now in remission. Doctors at Great Ormond Street Hospital have successfully treated five SCID patients, including toddler Rhys Evans, using a very similar technique to that in the French trial. Despite the risks of gene therapy, many scientists say it is still the best option for some patients: 'Although it is anguishing for parents to expose their children to the chance of developing cancer, the benefits of gene therapy for this devastating disease greatly outweigh the risks of the disease itself' said Terry Rabbitts of the UK's MRC Laboratory of Molecular Biology, who helped investigate the French cancer cases.

Commenting on the new study, David Williams and Christopher Baum wrote in a Science article that 'it would be unrealistic not to expect gene therapies to produce side effects'. Doctors at the Necker Hospital are now working on ways of making the treatment safer - treating only older children, injecting fewer modified bone marrow cells, or using different viruses to deliver the gene could all help reduce the risks. 'The bottom line is that gene therapy works, there is no question about that. It works too well to stop trying it' said team leader Alain Fischer.

Doctors discover why gene therapy gave boys cancer
The Guardian |  17 October 2003
Gene therapy 'caused leukaemia'
BBC News Online |  16 October 2003
Gene therapy did cause cancer in boys, study shows
Reuters |  16 October 2003
Gene therapy - new challenges ahead
Science |  17 October 2003
5 February 2018 - by Ewa Zotow 
Animals given high doses of gene-carrying viruses in a new gene-therapy trial showed signs of severe toxicity.
4 April 2011 - by Maren Urner 
Researchers from the Wellcome Trust Sanger Institute have identified three different genetic mutations linked to acute myeloid leukaemia (AML), a cancer that is characterised by a rapid increase in abnormal white blood cells in the bone marrow....
2 February 2009 - by Dr Megan Allyse 
Researchers in Italy and Israel have announced that they have successfully used gene therapy to treat ten children who suffer from a rare form of severe combined immunodeficiency (SCID) called ADA-SCID. The trial marks one of the first successful uses of gene therapy since past trials of...
27 April 2006 - by BioNews 
Replacement genes used to treat an inherited immune disorder could trigger cancer, new research carried out on rodents suggests. The study, published in the journal Nature, shows that treating mice with a normal copy of the gene defective in X-linked severe combined immune deficiency (X-SCID) results in cancer of the...
7 March 2005 - by BioNews 
The US Food and Drug Administration (FDA) has recommended that gene therapy treatments for an inherited immune disorder are limited to those who have no alternative. The move follows news that a third child in a similar French trial has developed leukaemia. The trial for X-linked severe combined immunodeficiency disorder...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.